Fig. 6

Proteome analysis of PANC-1 cells exposed to avasimibe, with or without oleic acid. Cells treated with avasimibe (AVA; 5 µM), oleic acid (OA; 100 µM) or AVA + OA for 48 h prior to LC–MS/MS. A. PCA-sample plot in which each dot represents an individual sample colored according to the treatment group. B. PCA-variable plot showing the distribution of differentially expressed proteins (DEPs) between control and AVA-treated samples; each dot represents an individual protein. C-D. Heatmaps showing the distribution of all proteins with > twofold (in C; n = 289) and > fivefold (in D; n = 28) change in expression between AVA-treated and control samples. E. STRING network and F. Gene ontology enrichment of biological processes and KEGG pathway of DEPs (presented in D). G. Bar diagrams for selected DEPs (from D) with similar expression pattern across all samples from the same treatment group. H. Validation of SCD and CLU protein expressions by immunoblotting. CLU clusterin, CYP51A1 cytochrome P450 family 51 subfamily A member 1, FADS2 fatty acid desaturase 2, LFQ label-free quantitation, LGALS8 Galectin 8, NID1 Nidogen 1, RSU1 Ras suppressor protein 1, SCD stearoyl-CoA desaturase, VWA1, von Willebrand factor A domain containing 1